Veer Biotech signs $1.71 billion deal with Astellasinvestor’s business daily
Astellas and Vir Biotechnology announce a global strategic collaboration to advance the PSMA-targeted PRO-XTEN® dual-masked T-cell engager VIR-5500 for the treatment of prostate cancer.PR Newswire
Astellas pays $240M cash for Veer’s prostate cancer drugendpoint news
Prostate cancer cure, 88% hepatitis delta response, cash runway by 2028 in Veerstock titan
Astellas has collaborated with Veer to develop its experimental prostate cancer drugyahoo finance
